Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
Panacea Biotec, India’s second largest producer of vaccines and a highly progressive research based health management company is reportedly awaiting World Health Organization’s (WHO) approval to resume supplying vaccines for the world immunisation programme from its units at Lalru (Haryana) and Baddi (Himachal Pradesh).
Further towards this development, the company is expecting WHO’s officials to visit its units in Lalru and Baddi for prequalification next month after having recently shifted its Easy five pentavalent vaccine to its new unit in Baddi, which may aid the company in grabbing the next supply deal.
Companies are qualified to bid for WHO tenders to supply drugs only if their vaccines are in the list of prequalified vaccines. Panacea manufactured the five-in-one vaccine, used to treat diphtheria, pertussis, tetanus, haemophilus influenza B and hepatitis B in children, at its unit in Delhi and the raw material at the Lalru unit.
However, in mid-2011, WHO delisted the Lalru unit, citing irregularities and deficiencies in the plant’s quality management system. As a result, three of the company’s diptheria-pertussis-tetanus-based combination vaccines, Easyfive, Ecovac4 and EnivacHB, were also delisted from WHO’s list of pre-qualified vaccines. Additionally, back in March 2012, Panacea had voluntarily withdrawn its oral polio vaccine, or OPV, (also produced at the company’s Delhi facility) from WHO’s list of pre-qualified vaccines, reasoning the manufacturing unit needed corrective action.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1687.55 |
Dr. Reddys Lab | 1109.15 |
Cipla | 1463.15 |
Lupin | 1969.05 |
Zydus Lifesciences | 868.25 |
View more.. |